Form 4: Moderna Chief Legal Officer Reports Stock Transactions Following RSU Vesting

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the acquisition of 1,139 common shares from restricted stock unit vesting and the disposition of 551 shares for tax obligations on June 6, 2025, resulting in a beneficial ownership of 27,483 shares.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc. (MRNA), reported stock transactions that occurred on June 6, 2025.
• She acquired 1,139 shares of Moderna common stock upon the vesting and conversion of restricted stock units (RSUs).
• Concurrently, 551 shares were disposed of at a price of $26.12 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Ms. Klinger directly beneficially owns 27,483 shares of Moderna common stock.
• The RSU award, from which the 1,139 shares originated, fully vested as of June 6, 2025, with an initial vesting of 25% on June 7, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.
• The reported beneficial ownership also includes 595 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 30, 2025.

Sentiment

Score: 6

Explanation: The document is a routine insider transaction report. The vesting of RSUs and acquisition of shares through ESPP are generally positive as they indicate executive alignment and compensation fulfillment, but the disposition for tax purposes is a neutral, standard event. No significant positive or negative operational news is conveyed.

Positives

• The vesting of restricted stock units indicates the fulfillment of long-term incentive compensation for a key executive, aligning their interests with shareholders.
• The executive's continued beneficial ownership of a significant number of shares (27,483) demonstrates ongoing commitment to the company.
• The acquisition of 595 shares through the Employee Stock Purchase Plan (ESPP) on May 30, 2025, further indicates executive investment in the company.

Negatives

• The disposition of 551 shares, while for tax withholding purposes, represents a reduction in the gross number of shares received from the RSU vesting.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, as its purpose is solely to report insider transactions.

Industry Context

This filing is a routine insider transaction report for a pharmaceutical and biotechnology company. It reflects standard executive compensation practices involving restricted stock units and employee stock purchase plans, common across many industries, including the biotech sector, to align executive interests with shareholder value.

Comparison to Industry Standards

• The reported transactions, specifically the vesting of restricted stock units and subsequent share withholding for taxes, are standard practices for executive compensation in publicly traded companies, including those in the biotechnology and pharmaceutical industries.
• The price of $26.12 for tax withholding is a specific transaction detail and not a benchmark for industry comparison.
• The number of shares beneficially owned by the Chief Legal Officer (27,483) is a specific figure for this individual and company, and its significance would typically be assessed in the context of the executive's overall compensation package and the company's market capitalization, rather than against a direct industry standard for share ownership.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices and the executive's continued equity ownership, aligning interests.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates a benefit available to employees.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, RSU, Executive Compensation, Shannon Thyme Klinger, Chief Legal Officer, Employee Stock Purchase Plan, ESPP